Invivyd (IVVD) Net Equity Issued and Repurchased (2021 - 2025)
Invivyd's (IVVD) quarterly Net Equity Issued and Repurchased came in at $10.9 million in Q4 2025, up 33962.5% on a YoY basis from N/an in Q4 2024, and up 13874.36% quarter-over-quarter from $78000.0 in Q2 2025.
Analysis
Invivyd (IVVD) Net Equity Issued and Repurchased (2021 - 2025) Analysis & Trends
Invivyd (IVVD) has reported Net Equity Issued and Repurchased for 5 consecutive years, with $10.9 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Net Equity Issued and Repurchased rose 33962.5% year-over-year to $10.9 million; the trailing twelve-month figure through Dec 2025 stood at $11.1 million (up 4856.95% YoY), and the FY2025 full-year result was $254000.0, up 13.9% from the prior year.
- Net Equity Issued and Repurchased rose to $10.9 million in Q4 2025 per IVVD's latest filing, from $78000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $10.9 million in Q4 2025 and bottomed at -$101000.0 in Q3 2021.
- Historically, Net Equity Issued and Repurchased has averaged $832357.1 across 5 years, with a median of $66000.0 in 2023.
- The sharpest annual moves came in 2023 and 2025: Net Equity Issued and Repurchased plunged 63.33% in 2023, then surged 33962.5% in 2025.
- Over 5 years, Net Equity Issued and Repurchased stood at -$101000.0 in 2021, then jumped by 218.81% to $120000.0 in 2022, then slumped by 63.33% to $44000.0 in 2023, then dropped by 27.27% to $32000.0 in 2024, then soared by 33962.5% to $10.9 million in 2025.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $10.9 million, $78000.0, and $44000.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 9.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 49.20 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 10.90 Mn |
| Jun 30, 2025 | 78,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Dec 31, 2024 | 32,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Jun 30, 2024 | 75,000.00 |
| Mar 31, 2024 | 89,000.00 |
| Dec 31, 2023 | 44,000.00 |
| Sep 30, 2023 | 57,000.00 |
| Jun 30, 2023 | 56,000.00 |
| Mar 31, 2023 | 83,000.00 |
| Dec 31, 2022 | 120,000.00 |
| Sep 30, 2022 | 149,000.00 |
| Sep 30, 2021 | -101,000.00 |